Abstract
Background Quantifying antibody reactivity to SARS-CoV-2 antigens in unexposed individuals through the pandemic may help understand its effect on COVID-19 severity at the population level. This antibody reactivity may be particularly prevalent among childcare providers, including pediatric health care workers (HCW) who may be more exposed to circulating coronaviruses.
Methods Cross-sectional study that included adults in the Vancouver area in British Columbia (BC), Canada, between May 17 and June 19, 2020. SARS-CoV-2 seroprevalence was ascertained by measuring total SARS-CoV-2 IgG/M/A antibodies against a recombinant spike (S1) protein, and adjusted for bias due to false-positive and false-negative test results. A novel multiple antibody assay was also used to profile IgG reactivity against four SARS-CoV-2 antigens, SARS-CoV and four circulating coronaviruses.
Findings Among 276 participants (71% HCW), three showed evidence of direct viral exposure, yielding an adjusted seroprevalence of 0.60% [95%CI 0% – 2.71%], with no difference between HCW and non-HCW, or between paediatric and adult HCW. Among the remaining 273 unexposed individuals, 7.3% [95%CI 4.5% – 11.1%], 48.7 [95%CI 42.7% – 54.8%] and 82.4% [95%CI 77.4% – 86.7%] showed antibody reactivity against SARS-CoV-2 RBD, N or Spike proteins, respectively. This reactivity was evenly distributed as a function of age, sex or between pediatric and adult HCW, and partly correlated with reactivity to circulating coronaviruses (Spearman rho ranging between 0.147 and 0.513 for significant correlation after a false-discovery rate adjustment at 5%).
Interpretation A substantial proportion of individuals in this population showed antibody reactivity against SARS-CoV-2 antigens despite low serological evidence of SARS-CoV-2 exposure.
Funding NIAID/NIH
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This study is not a clinical trial
Funding Statement
This study was supported by unrestricted grant funding to PML and an Intramural Research Program of the Vaccine Research Centre (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). The funders did not play a role in the design, planning, execution, analysis or publication of the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the University of British Columbia Children's & Women's Research Ethic Board (H20-01205).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Dr. Pascal Lavoie had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Data Availability
Non-identifying metadata will be provided (in process); participant specific demographic data may be made available later, or to external investigators upon request, if can be agreed by participants and after obtaining permissions from relevant institutional ethics review boards...
